Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Consolidated Net Income (2020 - 2025)

Bioventus (BVS) has disclosed Consolidated Net Income for 5 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Consolidated Net Income changed N/A year-over-year to $17.3 million, compared with a TTM value of $27.3 million through Dec 2025, changed N/A, and an annual FY2025 reading of $27.3 million, changed N/A over the prior year.
  • Consolidated Net Income was $17.3 million for Q4 2025 at Bioventus, up from $4.0 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $24.5 million in Q2 2021 and bottomed at -$74.4 million in Q2 2023.
  • Average Consolidated Net Income over 4 years is -$8.0 million, with a median of -$401000.0 recorded in 2022.
  • The sharpest move saw Consolidated Net Income surged 133.91% in 2021, then crashed 93484.0% in 2022.
  • Year by year, Consolidated Net Income stood at -$25000.0 in 2021, then plummeted by 93484.0% to -$23.4 million in 2022, then tumbled by 218.13% to -$74.4 million in 2023, then surged by 123.27% to $17.3 million in 2025.
  • Business Quant data shows Consolidated Net Income for BVS at $17.3 million in Q4 2025, $4.0 million in Q3 2025, and $9.3 million in Q2 2025.